GSK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. GlaxoSmithKline PLC's research and development for the three months ended in Jun. 2016 was $1,261 Mil. Its research and development for the trailing twelve months (TTM) ended in Jun. 2016 was $5,269 Mil.
This is the expense the company spent on research and development.
GlaxoSmithKline PLC Research & Development for the trailing twelve months (TTM) ended in Jun. 2016 was 1268.40490798 (Sep. 2015 ) + 1577.84431138 (Dec. 2015 ) + 1160.96866097 (Mar. 2016 ) + 1261.36363636 (Jun. 2016 ) = $5,269 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
GlaxoSmithKline PLC Annual Data
|Research & Development||6,790||6,533||5,470||6,666||6,953||6,254||6,410||6,421||5,399||5,329|
GlaxoSmithKline PLC Quarterly Data
|Research & Development||1,427||1,369||1,308||1,532||1,296||1,265||1,268||1,578||1,161||1,261|